Lv2
110 积分 2021-09-23 加入
Thoracic radiotherapy synergizes with first‐line EGFR ‐ TKIs in advanced EGFR ‐mutant NSCLC : A dual‐center real‐world study
24天前
已完结
Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase–driven non-small cell lung cancer therapy
1个月前
已完结
962eP Befotertinib (D-0316) plus icotinib as first-line therapy for patients with EGFR-mutated advanced non-small-cell lung cancer
1个月前
已关闭
Safety and Efficacy of the Oral IL-23 Receptor Antagonist Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
1个月前
已完结
Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR -Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study
1个月前
已完结
1081eP EGFR exon 19 duplications/insertions, rare but potential therapeutic targets for NSCLC: A real-world study and pooled analysis of case series
1个月前
已关闭
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer
1个月前
已关闭
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
1个月前
已完结
Successful Treatment of Switching EGFR-TKIs for Advanced Lung Adenocarcinoma Due to Interstitial Lung Disease: A Case Report
3个月前
已完结
Establishment and characterization of a novel imatinib-resistant dermatofibrosarcoma protuberans cell line, DFSP-DPH1
3个月前
已完结
皖公网安备34019202002308
